Skip to content 
Tirzepatide: The Next‑Generation Dual Agonist for Diabetes and Obesity
Keywords: Tirzepatide, dual GIP/GLP‑1 agonist, weight loss, type 2 diabetes, SURPASS, SURMOUNT, cardiovascular, adverse effects 1. Overview & Discovery Tirzepatide (brand names Mounjaro® for diabetes and Zepbound® for weight loss) is a groundbreaking 39–amino acid peptide developed by Eli Lilly that activates both the glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors simultaneously Reuters+15维基百科+15新英格兰医学杂志+15. […]
What Are Peptides? Their History and Their Impact on Human Health
Unlocking the potential of peptides—tiny biomolecules that play a big role in medicine, cosmetics, and life sciences. 1. 🧬 What Are Peptides? Peptides are short chains of amino acids, typically consisting of 2 to 50 residues linked by peptide bonds. These bonds form through a dehydration reaction between amino and carboxyl groups of adjacent amino […]
